NCT05221359View on ClinicalTrials.gov

Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes

NARecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Type 1 DiabetesType 1 Diabetes Mellitus With Hypoglycemia
Interventions
DEVICE

ExOlin®

"Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up."

DRUG

Insulin aspart

Use of NovoRapid insulin during all periods of the clinical investigations

Trial Locations (1)

67000

RECRUITING

Hôpitaux Universitaires de Strasbourg, Strasbourg

Sponsors

Lead Sponsor

Defymed
All Listed Sponsors
lead

Defymed

INDUSTRY